JP2020523384A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523384A5
JP2020523384A5 JP2019569364A JP2019569364A JP2020523384A5 JP 2020523384 A5 JP2020523384 A5 JP 2020523384A5 JP 2019569364 A JP2019569364 A JP 2019569364A JP 2019569364 A JP2019569364 A JP 2019569364A JP 2020523384 A5 JP2020523384 A5 JP 2020523384A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
lymphoma
seq
adc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019569364A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523384A (ja
Filing date
Publication date
Priority claimed from GBGB1709439.2A external-priority patent/GB201709439D0/en
Priority claimed from GBGB1709441.8A external-priority patent/GB201709441D0/en
Priority claimed from GBGB1710496.9A external-priority patent/GB201710496D0/en
Priority claimed from GBGB1710493.6A external-priority patent/GB201710493D0/en
Priority claimed from GBGB1720544.4A external-priority patent/GB201720544D0/en
Priority claimed from GBGB1720541.0A external-priority patent/GB201720541D0/en
Priority claimed from GBGB1803298.7A external-priority patent/GB201803298D0/en
Application filed filed Critical
Priority claimed from PCT/EP2018/065862 external-priority patent/WO2018229218A1/en
Publication of JP2020523384A publication Critical patent/JP2020523384A/ja
Publication of JP2020523384A5 publication Critical patent/JP2020523384A5/ja
Pending legal-status Critical Current

Links

JP2019569364A 2017-06-14 2018-06-14 抗ｃｄ２５ ａｄｃを投与するための投与レジメ Pending JP2020523384A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
GB1709439.2 2017-06-14
GBGB1709439.2A GB201709439D0 (en) 2017-06-14 2017-06-14 Dosage regime
GBGB1709441.8A GB201709441D0 (en) 2017-06-14 2017-06-14 Dosage regime
GB1709441.8 2017-06-14
GBGB1710496.9A GB201710496D0 (en) 2017-06-30 2017-06-30 Dosage regime
GB1710496.9 2017-06-30
GBGB1710493.6A GB201710493D0 (en) 2017-06-30 2017-06-30 Dosage regime
GB1710493.6 2017-06-30
GBGB1720544.4A GB201720544D0 (en) 2017-12-08 2017-12-08 Dosage regime
GBGB1720541.0A GB201720541D0 (en) 2017-12-08 2017-12-08 Dosage regime
GB1720541.0 2017-12-08
GB1720544.4 2017-12-08
GBGB1803298.7A GB201803298D0 (en) 2018-02-28 2018-02-28 Dosage regime
GB1803298.7 2018-02-28
PCT/EP2018/065862 WO2018229218A1 (en) 2017-06-14 2018-06-14 Dosage regimes for the administration of an anti-cd25 adc

Publications (2)

Publication Number Publication Date
JP2020523384A JP2020523384A (ja) 2020-08-06
JP2020523384A5 true JP2020523384A5 (https=) 2021-07-26

Family

ID=62636210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019569364A Pending JP2020523384A (ja) 2017-06-14 2018-06-14 抗ｃｄ２５ ａｄｃを投与するための投与レジメ

Country Status (9)

Country Link
US (2) US11426467B2 (https=)
EP (1) EP3638372A1 (https=)
JP (1) JP2020523384A (https=)
KR (1) KR20200028950A (https=)
AU (1) AU2018285455A1 (https=)
BR (1) BR112019026498A2 (https=)
CA (1) CA3064681A1 (https=)
MX (1) MX2019014923A (https=)
WO (1) WO2018229218A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3098103A1 (en) * 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN114302746A (zh) * 2019-06-10 2022-04-08 Adc治疗有限公司 包含抗cd25抗体药物缀合物和另一剂的组合疗法
GB201917254D0 (en) * 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
WO2025051254A1 (zh) * 2023-09-08 2025-03-13 信达生物制药(苏州)有限公司 半胱氨酸改造的抗体和免疫缀合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
CA2717915A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
WO2014057118A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
EP2906296B1 (en) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
RS57694B1 (sr) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pirolobenzodiazepin - anti-psma konjugati antitela
HRP20182129T1 (hr) * 2012-10-12 2019-02-08 Adc Therapeutics Sa Konjugati protutijelo - pirolobenzodiazepin
SI2906252T1 (sl) 2012-10-12 2017-10-30 Adc Therapeutics Sa Pirolobenzodiazepin-anti-HER2 protitelesni konjugati
JP6392765B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US20160256561A1 (en) 2013-10-11 2016-09-08 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
CN107148285B (zh) * 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
GB201506388D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W Site-specific antibody-drug conjugates
GB201506393D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506405D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506394D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506407D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506409D0 (en) 2015-04-15 2015-05-27 Williams David G And Berkel Patricius H C Van And Howard Philip W Humanized anti-axl antibodies and their conjugates
GB201506399D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201507827D0 (en) 2015-05-07 2015-06-17 Adc Therapeutics Sarl Diagnostic test
GB201513607D0 (en) * 2015-07-31 2015-09-16 Feingold Jay M Pyrrolobenzodiazepine-antibody conjugates
CN108025023A (zh) * 2015-08-25 2018-05-11 Uab研究基金会 用于干细胞移植的方法

Similar Documents

Publication Publication Date Title
JP2020523384A5 (https=)
JP6628828B2 (ja) Ｈｉｖを治療するためのトール様受容体の調節因子
JP2014533279A5 (https=)
JP2019506403A5 (https=)
JP2015534579A5 (https=)
JP2015529225A5 (https=)
JP2021502961A5 (https=)
JP2018506550A5 (https=)
CN114286828A (zh) 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
JP2015532292A5 (https=)
JP2020524670A5 (https=)
JP2014114288A5 (https=)
JP2019517485A5 (https=)
HRP20180945T1 (hr) Konjugati protutijelo-pirolobenzodiazepin
JP2013517277A5 (https=)
TW201919699A (zh) 包含抗-cd38抗體及雷那度胺(lenalidomide)之組合物
JP2021523122A5 (https=)
JP6184952B2 (ja) 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法
RU2014117510A (ru) Лечение ревматоидного артрита
JP2019533682A5 (https=)
JP2020502219A5 (https=)
JP2018515493A5 (https=)
JP2016094424A5 (https=)
JP2014525926A5 (https=)
JP2019532970A5 (https=)